Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward

Takeda and Lundbeck-partnered rare neurological disorder company Ovid Therapeutics has some encouraging mid-stage data from a Fragile X study testing its lead drug, but there remain questions about the optimal dose to take forward into a pivotal trial.